Job Listings

Track Jounce Therapeutics hiring and firing trends, filtered by title, location, type, date, category and date of posting.

Rows

Open dataset
Ticker Symbol Entity Name Domain As Of Date Title URL Brand Category Location Text City State Country Posted Date Number of Openings Description Salary Salary Currency Salary Description Coordinates Date Added Date Updated Company Name Sector Industry
nasdaq:jnce careers-jouncetx.icims.com careers-jouncetx.icims.com Sep 9th, 2020 12:00AM Medical Director / Senior Medical Director Open Jounce Therapeutics Clinical Development Cambridge, MA, 02139, USA MA Cambridge USA Jun 24th, 2019 12:00AM Job Title Medical Director / Senior Medical Director Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce currently has four development-stage programs, two of which are clinical-stage: vopratelimab, a monoclonal antibody that binds to and activates ICOS, and JTX-4014, a PD-1 inhibitor intended for combination use with Jounce’s broader pipeline. Vopratelimab is currently being assessed in a Phase 2 clinical trial, EMERGE, and Jounce plans to initiate an additional Phase 2 biomarker trial using TISvopra for patient selection, SELECT, to assess vopratelimab in combination with JTX-4014. Jounce’s IND-enabling preclinical programs include JTX-8064, a LILRB2 receptor antagonist and JTX-1811, a monoclonal antibody designed to selectively deplete T regulatory cells in the tumor microenvironment. For more information, please visit www.jouncetx.com. Job ID 2019-1190 Location US-MA-Cambridge Sep 9th, 2020 01:13PM Sep 9th, 2020 01:13PM Jounce Therapeutics
nasdaq:jnce careers-jouncetx.icims.com careers-jouncetx.icims.com Sep 9th, 2020 12:00AM Clinical Trial Associate (CTA) Open Jounce Therapeutics Clinical Operations Cambridge, MA, 02139, USA MA Cambridge USA Jul 30th, 2020 12:00AM Job Title Clinical Trial Associate (CTA) Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce is developing two clinical-stage programs as well as advancing and building out its broad and wholly-owned discovery pipeline of immuno-oncology targets, including those expressed on T-regulatory cells, macrophages and stromal cells. Jounce’s lead product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS and is currently being assessed in a Phase 2 clinical trial. JTX-4014 is a PD-1 inhibitor intended for use in combination with future pipeline products, and Jounce has completed enrollment in the JTX-4014 Phase 1 clinical trial. In addition, Jounce has exclusively licensed worldwide rights to JTX-8064, a LILRB2 receptor antagonist, to Celgene. For more information, please visit www.jouncetx.com. Job ID 2020-1206 Location US-MA-Cambridge Sep 9th, 2020 01:13PM Sep 9th, 2020 01:13PM Jounce Therapeutics
nasdaq:jnce careers-jouncetx.icims.com careers-jouncetx.icims.com Sep 11th, 2020 12:00AM Clinical Trial Associate (CTA) Open Jounce Therapeutics Clinical Operations Cambridge, MA, 02139, USA MA Cambridge USA Jul 30th, 2020 12:00AM Job Title Clinical Trial Associate (CTA) Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce is developing two clinical-stage programs as well as advancing and building out its broad and wholly-owned discovery pipeline of immuno-oncology targets, including those expressed on T-regulatory cells, macrophages and stromal cells. Jounce’s lead product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS and is currently being assessed in a Phase 2 clinical trial. JTX-4014 is a PD-1 inhibitor intended for use in combination with future pipeline products, and Jounce has completed enrollment in the JTX-4014 Phase 1 clinical trial. In addition, Jounce has exclusively licensed worldwide rights to JTX-8064, a LILRB2 receptor antagonist, to Celgene. For more information, please visit www.jouncetx.com. Job ID 2020-1206 Location US-MA-Cambridge Sep 11th, 2020 02:29AM Sep 11th, 2020 02:29AM Jounce Therapeutics
nasdaq:jnce careers-jouncetx.icims.com careers-jouncetx.icims.com Sep 11th, 2020 12:00AM Associate / Sr. Associate Scientist Open Jounce Therapeutics Research & Development Cambridge, MA, 02139, USA MA Cambridge USA Sep 2nd, 2020 12:00AM Job Title Associate / Sr. Associate Scientist Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce currently has four development-stage programs, two of which are clinical-stage: vopratelimab, a monoclonal antibody that binds to and activates ICOS, and JTX-4014, a PD-1 inhibitor intended for combination use with Jounce’s broader pipeline. Vopratelimab is currently being assessed in a Phase 2 clinical trial, EMERGE, and Jounce plans to initiate an additional Phase 2 biomarker trial using TISvopra for patient selection, SELECT, to assess vopratelimab in combination with JTX-4014. Jounce’s IND-enabling preclinical programs include JTX-8064, a LILRB2 receptor antagonist and JTX-1811, a monoclonal antibody designed to selectively deplete T regulatory cells in the tumor microenvironment. For more information, please visit www.jouncetx.com. Job ID 2020-1218 Location US-MA-Cambridge Sep 11th, 2020 02:29AM Sep 11th, 2020 02:29AM Jounce Therapeutics
nasdaq:jnce careers-jouncetx.icims.com careers-jouncetx.icims.com Oct 23rd, 2020 12:00AM Clinical Trial Manager Open Jounce Therapeutics Clinical Operations Cambridge, MA, 02139, USA MA Cambridge USA Sep 22nd, 2020 12:00AM Job Title Clinical Trial Manager Company Overview Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development-stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s lead product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the EMERGE Phase 2 trial. Vopratelimab will also be evaluated in the Phase 2 SELECT trial in combination with Jounce’s internal investigational PD-1 inhibitor, JTX-4014, in biomarker selected patients using TISvopra. Jounce’s next clinical candidate, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state. Additionally, Jounce has agreed to exclusively license worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences. For more information, please visit www.jouncetx.com.   Equal Opportunity Employer Jounce Therapeutics is an equal opportunity employer and does not discriminate in it’s employment decisions on the basis of race, color, national origin, age, physical or mental disability, marital status, religion, creed, sex, or political beliefs.  We offer a competitive salary and benefits package. All applicants should be legally entitled to work for any employer in the U.S.     To apply, please visit https://careers-jouncetx.icims.com/.   Job ID 2020-1219 Location US-MA-Cambridge Oct 23rd, 2020 02:20AM Oct 23rd, 2020 02:20AM Jounce Therapeutics
nasdaq:jnce careers-jouncetx.icims.com careers-jouncetx.icims.com Oct 23rd, 2020 12:00AM Director/Senior Director, Head of Discovery Open Jounce Therapeutics Research & Development Cambridge, MA, 02139, USA MA Cambridge USA Oct 9th, 2020 12:00AM Job Title Director/Senior Director, Head of Discovery Company Overview Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development-stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s lead product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the EMERGE Phase 2 trial. Vopratelimab will also be evaluated in the Phase 2 SELECT trial in combination with Jounce’s internal investigational PD-1 inhibitor, JTX-4014, in biomarker selected patients using TISvopra. Jounce’s next clinical candidate, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state. Additionally, Jounce has agreed to exclusively license worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences. For more information, please visit www.jouncetx.com.   Equal Opportunity Employer Jounce Therapeutics is an equal opportunity employer and does not discriminate in its employment decisions on the basis of race, color, national origin, age, physical or mental disability, marital status, religion, creed, sex, or political beliefs.  We offer a competitive salary and benefits package. All applicants should be legally entitled to work for any employer in the U.S. Job ID 2020-1223 Location US-MA-Cambridge Oct 23rd, 2020 02:20AM Oct 23rd, 2020 02:20AM Jounce Therapeutics
nasdaq:jnce careers-jouncetx.icims.com careers-jouncetx.icims.com Oct 23rd, 2020 12:00AM Principal Scientist, Discovery Open Jounce Therapeutics Research & Development Cambridge, MA, 02139, USA MA Cambridge USA Oct 9th, 2020 12:00AM Job Title Principal Scientist, Discovery Company Overview Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce currently has four development-stage programs, two of which are clinical-stage: vopratelimab, a monoclonal antibody that binds to and activates ICOS, and JTX-4014, a PD-1 inhibitor intended for combination use with Jounce’s broader pipeline. Vopratelimab is currently being assessed in a Phase 2 clinical trial, EMERGE, and Jounce plans to initiate an additional Phase 2 biomarker trial using TISvopra for patient selection, SELECT, to assess vopratelimab in combination with JTX-4014. Jounce’s IND-enabling preclinical programs include JTX-8064, a LILRB2 receptor antagonist and JTX-1811, a monoclonal antibody designed to selectively deplete T regulatory cells in the tumor microenvironment. For more information, please visit www.jouncetx.com. Job ID 2020-1222 Location US-MA-Cambridge Oct 23rd, 2020 02:20AM Oct 23rd, 2020 02:20AM Jounce Therapeutics
nasdaq:jnce careers-jouncetx.icims.com careers-jouncetx.icims.com Oct 24th, 2020 12:00AM Associate / Sr. Associate Scientist Open Jounce Therapeutics Research & Development Cambridge, MA, 02139, USA MA Cambridge USA Sep 2nd, 2020 12:00AM Job Title Associate / Sr. Associate Scientist Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce currently has four development-stage programs, two of which are clinical-stage: vopratelimab, a monoclonal antibody that binds to and activates ICOS, and JTX-4014, a PD-1 inhibitor intended for combination use with Jounce’s broader pipeline. Vopratelimab is currently being assessed in a Phase 2 clinical trial, EMERGE, and Jounce plans to initiate an additional Phase 2 biomarker trial using TISvopra for patient selection, SELECT, to assess vopratelimab in combination with JTX-4014. Jounce’s IND-enabling preclinical programs include JTX-8064, a LILRB2 receptor antagonist and JTX-1811, a monoclonal antibody designed to selectively deplete T regulatory cells in the tumor microenvironment. For more information, please visit www.jouncetx.com. Job ID 2020-1218 Location US-MA-Cambridge Oct 24th, 2020 02:04AM Oct 24th, 2020 02:04AM Jounce Therapeutics
nasdaq:jnce careers-jouncetx.icims.com careers-jouncetx.icims.com Oct 24th, 2020 12:00AM Principal Scientist, Discovery Open Jounce Therapeutics Research & Development Cambridge, MA, 02139, USA MA Cambridge USA Oct 9th, 2020 12:00AM Job Title Principal Scientist, Discovery Company Overview Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce currently has four development-stage programs, two of which are clinical-stage: vopratelimab, a monoclonal antibody that binds to and activates ICOS, and JTX-4014, a PD-1 inhibitor intended for combination use with Jounce’s broader pipeline. Vopratelimab is currently being assessed in a Phase 2 clinical trial, EMERGE, and Jounce plans to initiate an additional Phase 2 biomarker trial using TISvopra for patient selection, SELECT, to assess vopratelimab in combination with JTX-4014. Jounce’s IND-enabling preclinical programs include JTX-8064, a LILRB2 receptor antagonist and JTX-1811, a monoclonal antibody designed to selectively deplete T regulatory cells in the tumor microenvironment. For more information, please visit www.jouncetx.com. Job ID 2020-1222 Location US-MA-Cambridge Oct 24th, 2020 02:04AM Oct 24th, 2020 02:04AM Jounce Therapeutics
nasdaq:jnce careers-jouncetx.icims.com careers-jouncetx.icims.com Oct 25th, 2020 12:00AM Principal Scientist Open Jounce Therapeutics Research & Development Cambridge, MA, 02139, USA MA Cambridge USA Oct 5th, 2020 12:00AM Job Title Principal Scientist Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce currently has four development-stage programs, two of which are clinical-stage: vopratelimab, a monoclonal antibody that binds to and activates ICOS, and JTX-4014, a PD-1 inhibitor intended for combination use with Jounce’s broader pipeline. Vopratelimab is currently being assessed in a Phase 2 clinical trial, EMERGE, and Jounce plans to initiate an additional Phase 2 biomarker trial using TISvopra for patient selection, SELECT, to assess vopratelimab in combination with JTX-4014. Jounce’s IND-enabling preclinical programs include JTX-8064, a LILRB2 receptor antagonist and JTX-1811, a monoclonal antibody designed to selectively deplete T regulatory cells in the tumor microenvironment. For more information, please visit www.jouncetx.com. Job ID 2020-1216 Location US-MA-Cambridge Oct 25th, 2020 10:43AM Oct 25th, 2020 10:43AM Jounce Therapeutics

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.